Table 1.
Baseline Characteristics
| Study Population (n=400) | |
|---|---|
|
| |
| Age (years)* | 66.4 ± 14.1 |
|
| |
| Male, n (%) | 232 (58.0) |
|
| |
| Race, n (%) | |
| Black | 124 (31.0) |
| White | 272 (68.0) |
| Other | 4 (1.0) |
|
| |
| Ethnicity, n (%) | |
| Non-Hispanic | 352 (88) |
| Hispanic | 48 (12) |
|
| |
| Body Mass Index (kg/m2)* | 26.2 ± 6.8 |
|
| |
| Cause of End-Stage Renal Disease, n (%) | |
| Diabetes | 186 (46.5) |
| Other | 214 (53.5) |
|
| |
| Comorbidities, n (%) | |
| Hypertension | 149 (37.3) |
| Coronary Artery Disease/Myocardial Infarction | 46 (11.5) |
| Peripheral Vascular Disease | 20 (5.0) |
| Congestive Heart Failure | 50 (12.5) |
| Atrial Fibrillation | 13 (3.3) |
| Stroke | 15 (3.8) |
|
| |
| Initial Type of Vascular Access, n (%) | |
| First Access Fistula | 120 (31.1) |
| First Access Graft | 44 (14.3) |
| First Access Catheter | 211 (54.7) |
|
| |
| Systolic BP (mmHg)* | 142.8 ± 23.0 |
| Diastolic BP (mmHg)* | 72.6 ± 12.4 |
|
| |
| Medications, n (%) | |
| ACE inhibitor or ARB | 169 (42.3) |
| Beta Blocker | 243 (60.8) |
| Aspirin | 129 (32.3) |
| Statin | 159 (39.8) |
|
| |
| Pre-Dialysis Laboratory Values* | |
| Serum Albumin (g/dL) | 3.5 ± 0.5 |
| Serum Cholesterol (mg/dL) | 150.6 ± 46.0 |
| Serum Creatinine (mg/dL) | 6.1 ± 2.6 |
| Serum Ferritin (ng/ml) | 328.3 ± 583.2 |
| Serum Phosphorus (mg/dL) | 4.6 ± 1.6 |
| Serum Potassium (mEq/L) | 4.3 ± 0.6 |
| Serum Calcium (mg/dL) | 8.4 ± 0.8 |
| Serum PTH (pg/mL) | 263.1 ± 299.4 |
| Serum Alkaline Phosphatase (units/L) | 100.3 ± 71.3 |
| Serum Glucose (mg/dL) | 157.8 ± 78.5 |
| Hemoglobin (g/dL) | 10.3 ± 1.4 |
| White Blood Cells (x 103/μL) | 8.4 ± 3.3 |
*
Mean ± Standard Deviation
Reprinted with permission from reference 23 and S. Karger AG